TABLE 5.

Outcomes of representative clinical trials of gemcitabine in nonspecific STSs.

Drugs and dosages	Years of report	Study types	Setting	Number of patients	Outcomes			References
					ORR (%)	M-PFS (months)	M-OS (months)
Single agent
Gemcitabine 1,200 mg/m2/d1,8/3w	2007	Phase II trial	Any-line	49	8	3	11.5	Maki et al. (2007)
Gemcitabine 1,000 mg/m2/1w	2006	Phase II trial	First-line	46	7	2	6	Von Burton et al. (2006)
Gemcitabine 1,250 mg/m2/d1,8,15/4w	2003	Phase II trial	Any-line	25	4	-	15	Okuno et al. (2003)
Gemcitabine 1,250 mg/m2/d1,8/3w	2002	Phase II trial	≥2 line	31	3.23	1.5	8.9	Svancárová et al. (2002)
Combination regimens
Gemcitabine 1,000 mg/m2/d1,8/3w plus pazopanib 800 mg/d	2021	Phase II trial	≥2 line	45	11	4.1	12.4	Somaiah et al. (2021)
Gemcitabine 900 mg/m2/d1,8/3w plus docetaxel 100 mg/m2/d8/3w	2021	Phase II trial	≥2 line	45	18	4.1	15.9	Somaiah et al. (2021)
Gemcitabine 1,000 mg/m2/d1,8/3w plus pazopanib 800 mg/d	2021	Phase II trial	≥2 line	43	11	5.6	13.1	Schmoll et al. (2021)
Gemcitabine 900 mg/m2/d1,8/3w plus docetaxel 75 mg/m2/d8/3w	2019	Phase II trial	Any-line	70	20	5.6	21.1	Jones et al. (2019)
Gemcitabine 675 mg/m2/d1,8/3w plus docetaxel 75 mg/m2/d8/3w	2017	Phase III trial	First-line	128	20	5.5	15.7	Seddon et al. (2017)
Gemcitabine 1,000 mg/m2/d1,8/3w plus docetaxel 35 mg/m2/d1,8/3w	2012	Phase II trial	≥2 line	30	16.7	2.5	8.4	Lee et al. (2012)
Gemcitabine 1800 mg/m2/3w plus dacarbazine 500 mg/m2/2w	2011	Phase II trial	≥2 line	57	12	4.2	16.8	Garcia-Del-Muro et al. (2011)
Gemcitabine 800 mg/m2/d1,8/3w plus vinorelbine 25 mg/m2/d1,8/3w	2007	Phase II trial	Any-line	40	10	3.4	-	Dileo et al. (2007)

STSs, soft tissue sarcomas; ORR, objective response rate; M-PFS, median progression-free survival; M-OS, median overall survival.